Lynozyfic (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment
All three dose groups (50 mg, 100 mg and 200 mg) showed…
Press Release: Sanofis Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma
Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly…
